Viatris Inc. Website

Viatris Inc.

NasdaqGS-VTRS

Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

  • Name

    Viatris Inc.

  • CEO

    Scott Andrew Smith

  • Website

    www.viatris.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1961

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Recent additions to the pipeline, which span many attractive therapeutic areas, should support Viatris' long-term growth potential and margin expansion.

  • Effective portfolio optimization from divestitures and a promising pipeline of first-to-market generic launches should provide solid top-line tailwinds.

  • Exiting biosimilars business will reallocate resources and help the company focus on long-term goals in its core generic and branded markets.

Bears Say

  • Base business erosion will persist in developed markets and act as a headwind that Viatris must try to offset with new product launches.

  • Failure to develop its pipeline and launch products could cause the company to lag its competitors in terms of innovation and development, especially since Viatris has exited biosimilar opportunities.

  • The impact of pharmaceutical-specific tariffs on the generics industry remains uncertain and could weigh down Viatris' earnings.

Source: Morningstar Analysis - Nov 06, 2025

What's happening

Nov 13, 2025 - Dec 13, 2025

Viatris Inc. Surges Amid Strategic Moves and Analyst Endorsements

  • Viatris divests equity stake in Biocon Biologics Limited for $815 million, enhancing operational flexibility.
  • Barclays initiates coverage with an Overweight rating and a price target of $15 per share, boosting investor confidence.
  • Recognition as one of Fortune World's Best Workplaces highlights commitment to employee wellbeing.

Over the past month, Viatris Inc. (VTRS) experienced a notable increase of 6.0% in its stock price, significantly outperforming the S&P 500, which saw a slight decline of 0.2%. This performance translates into an overperformance of 6.2% relative to the S&P 500 index and is particularly impressive when compared to the Health Care sector (XLV), where VTRS outperformed by 5.2%. The upward trajectory was largely driven by several key developments that bolstered investor confidence.

On December 8, Viatris announced its decision to divest its equity stake in Biocon Biologics Limited for $815 million through cash and newly issued equity shares. This strategic move provided immediate capital while allowing Viatris to regain access to the biosimilars market globally much sooner than anticipated due to accelerated non-compete restrictions established earlier.

Additionally, Barclays initiated coverage on VTRS with an Overweight rating on December 9 and set a price target of $15 per share. This endorsement from a reputable financial institution further fueled bullish sentiment around the stock as it underscored analysts' recognition of Viatris's growth prospects amidst evolving market conditions.

Throughout November and early December, other positive indicators included advancements in VTRS’s late-stage pipeline along with new product launches aimed at driving future growth while maintaining sustainable operations through ongoing reviews. Furthermore, being recognized as one of Fortune World's Best Workplaces emphasized the company's commitment to employee wellbeing—a factor that can enhance productivity over time.

Despite these positive trends, there were moments reflecting bearish sentiment during announcements about upcoming healthcare conferences that did not generate significant excitement among investors at that time; however, overall momentum remained strong due to strategic initiatives focused on addressing global health challenges like antimicrobial resistance along with regulatory approvals for key products such as teduglutide from European authorities.

Overall, VTRS's performance illustrates robust strategic maneuvers coupled with favorable analyst sentiments contributing positively against broader market trends.

NasdaqGS:VTRS